HOUSE_OVERSIGHT_024727.jpg
1.24 MB
Extraction Summary
0
People
4
Organizations
9
Locations
1
Events
0
Relationships
3
Quotes
Document Information
Type:
Investment report / industry white paper
File Size:
1.24 MB
Summary
Page 91 of a 2017 report by Ackrell Capital discussing 'Global Cannabis Regulation.' The text outlines the momentum behind global cannabis legalization driven by medical recognition, listing countries with and without medical laws. It notes the conflict between U.S. federal and state laws and predicts Canada will legalize recreational use in mid-2018. The document bears a House Oversight Bates stamp.
Organizations (4)
| Name | Type | Context |
|---|---|---|
| Ackrell Capital, LLC |
Investment bank creating the report (Header/Footer)
|
|
| FINRA |
Ackrell Capital is a member (Footer)
|
|
| SIPC |
Ackrell Capital is a member (Footer)
|
|
| House Oversight Committee |
Source of the document production (Bates stamp)
|
Key Quotes (3)
"Cannabis legalization is gaining momentum around the world, offering global opportunities for cannabis companies and related businesses."Source
HOUSE_OVERSIGHT_024727.jpg
Quote #1
"Contrary to U.S. federal law, 29 states, encompassing 62% of the U.S. population, permit the production and possession of cannabis or concentrates for use in treating a broad range of qualifying medical conditions."Source
HOUSE_OVERSIGHT_024727.jpg
Quote #2
"Canada is widely expected to do so in mid-2018."Source
HOUSE_OVERSIGHT_024727.jpg
Quote #3
Full Extracted Text
Complete text extracted from the document (1,722 characters)
ACKRELL
CAPITAL
CAPITAL
CHAPTER V
Global Cannabis Regulation
Global Cannabis Regulation
■ Global Cannabis Legalization Momentum
Cannabis legalization is gaining momentum around the world, offering global opportunities for cannabis companies and related businesses. This momentum is driven primarily by the increasing recognition that cannabis may have a range of legitimate medicinal benefits and therapeutic applications.
At least 20 countries now have medical laws that facilitate patient access to cannabis or concentrates for treating specified medical conditions. Notable countries with such medical laws include Australia, Canada, Colombia and Germany; countries without such laws include China, Japan, Russia and the United States. (Contrary to U.S. federal law, 29 states, encompassing 62% of the U.S. population, permit the production and possession of cannabis or concentrates for use in treating a broad range of qualifying medical conditions.) While the merits of medical cannabis are currently driving legalization, we believe that—like Uruguay and numerous U.S. states—other countries will ultimately enact legislation permitting the production, sale and use of recreational cannabis. (Canada is widely expected to do so in mid-2018.)
Cannabis legalization is gaining momentum around the world, offering global opportunities for cannabis companies and related businesses. This momentum is driven primarily by the increasing recognition that cannabis may have a range of legitimate medicinal benefits and therapeutic applications.
At least 20 countries now have medical laws that facilitate patient access to cannabis or concentrates for treating specified medical conditions. Notable countries with such medical laws include Australia, Canada, Colombia and Germany; countries without such laws include China, Japan, Russia and the United States. (Contrary to U.S. federal law, 29 states, encompassing 62% of the U.S. population, permit the production and possession of cannabis or concentrates for use in treating a broad range of qualifying medical conditions.) While the merits of medical cannabis are currently driving legalization, we believe that—like Uruguay and numerous U.S. states—other countries will ultimately enact legislation permitting the production, sale and use of recreational cannabis. (Canada is widely expected to do so in mid-2018.)
The following world map illustrates select countries that (i) have enacted medical laws that facilitate patient access to cannabis or concentrates for treating specified medical conditions, (ii) have enacted recreational laws that permit the commercial production and sale of cannabis to adults for recreational and other uses, or (iii) include a state or province that has a cannabis law or policy in conflict with federal law.
© 2017 Ackrell Capital, LLC | Member FINRA / SIPC
91
HOUSE_OVERSIGHT_024727
91
HOUSE_OVERSIGHT_024727
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document